Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration

Table 1 Vascular endothelial growth facto levels, central macular thickness, and best-corrected visual acuity before and after intravitreal injection of bevacizumab in neovascular age macular degeneration

	Baseline	7d	30d	3 m
VEGF (pg/mL)	179.7 ± 88.369	44.2 ± 25.258	56.6 ± 17.788	84.4 ± 23.378
		P < 0.0001	P < 0.0001	P < 0.0001
BCVA (decimal)	0.044 ± 0.062	0.079 ± 0.079	0.102 ± 0.085	0.084 ± 0.075
		P 0.0020	P < 0.0001	P 0.0005
SD-OCT
CRT (μm)	407.0 ± 190.374	307.9 ± 94.128	294.8 ± 104.173	334.3 ± 104.904
		P 0.0018	P 0.0005	P 0.0198
MV (mm³)	11.992 ± 3.740	10.700 ± 2.325	10.338 ± 2.286	10.867 ± 2.290
		P 0.0346	P 0.0074	P 0.0647
MA (μm)	332.5 ± 104.318	297.7 ± 64.979	287.4 ± 63.545	299.6 ± 65.462
		P 0.0420	P 0.0091	P 0.0543

VEGF vascular endothelial growth factor, BCVA best-corrected visual acuity, SD-OCT spectral-domain optical coherence tomography, CRT central retinal thickness, MV macular volume, MA macular area, P P value (comparisons with baseline)
* Linear mixed models were used to compare time points

ISSN: 2056-9920